Stories in Life Sciences

Andrea McBeth left academia, became a naturopath, and made fecal transplant safe and shelf-stable. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Andrea McBeth, Founder and CEO of Thaena, to explore how she built a microbiome company around rigorous science and how her five-person team now uses AI across nearly everything they do. Andrea's path ran fro...

RNA therapy formulation is one of the most resource-intensive steps in preclinical development.  In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Ruben Lopez, Ph. D., Founder of Nanofacile, to explore how his Montreal-based biotech is changing how researchers and biotech companies approach LNP formulation. Ruben holds a Ph. D. from École de technologie s...

In vivo CAR therapy delivers cancer-fighting immune cell reprogramming through a simple injection, skipping the external manufacturing process that makes traditional CAR T therapy cost close to half a million dollars per patient.  In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Salim Dhanji, PhD, CEO and Co-Founder of ME Therapeutics Holdings Inc. (CSE:...

Sirona Dx pioneered the first commercial spatial-omics CRO service in 2018, giving biopharma access to spatial biology and single-cell analytics at the depth and regulatory rigor clinical programs require. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Nasry Yassa, PhD, CEO, and Andrew Brown, PhD, Chief Commercial Officer of Sirona Dx, to explore how t...

David Esposito spent 16 years in commercial leadership at Merck before stepping into the early-stage life sciences world. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with David Esposito, CEO of ONL Therapeutics, to explore what it takes to lead a clinical-stage biopharmaceutical company from one month of runway to a $65 million Series D and an active Pha...

Can the gut microbiome in the first year of life determine whether a child develops allergies, asthma, or atopic dermatitis?  In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Nikole Kimes, Ph. D., Co-Founder and CEO of Siolta Therapeutics, to explore the clinical evidence behind early-life microbiome intervention and what it means for the future of aller...

What separates a promising drug from a commercial product runs deeper than the science.  In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Michael Howell, Founder and President of Mountaineer Biosciences, to explore what it actually takes to move from scientific discovery to a commercially viable drug development strategy. Michael has spent 20+ years movi...

Open surgery accounts for a third of all surgical procedures. Paul Davison puts the market at 35 million cases in the U.S. annually, growing at 9% a year, and the core tool used in most of them dates to the 1920s.  In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Paul Davison, CEO and Co-founder of Lamina Surgical, to explore what it looks like to reimag...

Premature baby nutrition in most NICUs is standardized: the same fortification dose for every infant, regardless of gestational age, weight, or clinical profile. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Isabel Hoffmann, CEO of TellSpec and Preemie Health, to explore how a 30-second human milk sensor and personalized AI prescriptions are changing...

What if the supplement you have been taking for years has never actually been tested in human cells?  In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Leena Pradhan-Nabzdyk, Co-founder and CEO of Canomiks, to explore what standard chemical analysis misses and why biological testing at the cellular level changes what we know about supplement safety and ef...

Almost 2 million EKGs are performed every day worldwide. Every single one still requires ten wires, ten stickers, and hoping someone puts them in the right place. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Michael Cetta and Mark Zachary, Co-founders of Crimson Scientific, to explore how they are cutting EKG capture time in half and eliminating...

80% of serious accidents at home happen in the bathroom. Most of the equipment designed to prevent those accidents hasn't changed since the 1970s.  In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Vince Ehrenberg, Founder and Inventor of PeriChair, to explore what happens when a caregiver decides to solve the problem himself. Vince became a full-time car...

What if doctors could predict how a patient will respond to treatment before giving it? In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Manuel Opitz, CEO and Co-founder of Deep Eye Medical, to explore how predictive AI is shifting ophthalmology from reactive treatment to personalized, data-driven care. In ophthalmology today, the standard approach is tr...

More foreign inventors are filing U.S. patents than Americans. The system built to protect innovation has become increasingly difficult for the founders and researchers it was designed to serve. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Shem Lachhman, Managing Partner and Co-Founder of Menlo Park Patents, to break down what founders actually need...

What if the implant that fixes your bone could disappear once you've healed?  In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Vicky Ahuja, CEO of OsseoLabs, to explore how 3D-printed magnesium implants are changing what patients and surgeons can expect from bone repair. Unlike titanium implants that remain in the body permanently, OsseoLabs' magnesi...

A surgeon told him: "If you had sent me a good picture, I could have saved you the trip." That seven-hour ER wait with his son became the origin story for Predictive Healthcare. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Talal Ali Ahmad, Founder and CEO of Predictive Healthcare, to explore how AI is closing the visibility gap between hospital disch...

We have made enormous progress in drug discovery. Yet most therapies still fail when they reach humans. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Suleen Raad, Co-founder and Chief Operating Officer of Telescope Therapeutics, to explore why traditional animal models continue to fall short and how human-relevant biology paired with AI could change t...

Many promising cancer proteins are nearly impossible to detect. Not because of biology, but because of engineering. Christopher Wilson sits down with Jessika Valero Gonzalez, Chief Research Officer at BioClonal, to explore how advanced antibody engineering is unlocking targets that traditional methods and animal models miss. Jessika's path runs from chemistry and protein science into biotech leade...

Most food byproducts are thrown away or downcycled, taking their nutritional value with them. Christopher Wilson sits down with Nina Granucci, Co-founder and President of Green Spot Technologies, to explore how solid-state fermentation is transforming food waste into scalable, high-value functional ingredients. Green Spot Technologies works with fruit, vegetable, legume, and cereal side streams, t...

Most biotech founders are deeply fluent in their science. Fewer are fluent in the story that moves their market. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Karl Schmieder, Founder of MessagingLab and co-host of the Grow Everything podcast, to explore how strategic communication and narrative shape the path from discovery to commercialization. Karl'...

Most cancer therapies target tumors from a single angle. When tumors adapt and escape, treatment stops working. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Jennifer Altomonte, molecular biologist and founder of Fusix Biotech, to explore a different approach built on engineered viruses that attack tumors from multiple directions at once. Dr. Alto...

"You always realize you are already late. By the time that you apply the therapy, it's too late." What if early diagnostics became the new standard of care? In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Sonia Trigueros, Founder of NIVD and former Co-Director of the Nanotechnology Program at Oxford, to explore how nanotechnology, quantum materials,...

What does it take to turn a scientist into a successful biotech founder? In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Vanloan Nguyen, Founder and Executive Director of Berkeley Pharma Tech, to explore the realities of building and scaling life sciences startups from the ground up. Vanloan has navigated the full arc from bench scientist to angel inves...

Drug development is being reshaped by AI, precision medicine, and a growing culture of collaboration across the life sciences. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Kim Kjøller, CEO of Union Therapeutics, to explore what that transformation looks like from inside a leading biotech company. Dr. Kjøller draws on decades of experience in Big...

Artificial intelligence is reshaping how biotech companies are built, funded, and scaled. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Michael Schrader, Co-founder and former CEO of Vaxess Technologies, to explore what that shift means for the next generation of founders. Michael's path from mechanical engineer to biotech entrepreneur spans mission-d...